| Today’s Big NewsJun 11, 2024 |
| By Annalee Armstrong Eli Lilly’s Alzheimer’s treatment sailed through an FDA advisory committee meeting Monday, with panelists praising the therapy as innovative—while also cautioning about a lack of data on specific subgroups. |
|
|
|
By Gabrielle Masson Johnson & Johnson Executive Vice President and Chief External Innovation and Medical Officer William Hait, M.D., Ph.D., will be hanging up his hat this September. |
By Fraiser Kansteiner Though not for lack of business development capacity, Pfizer is currently taking a large dealmaking “breathing period,” CEO Albert Bourla told investors this week at Goldman Sachs’ 2024 annual Global Healthcare Conference in Miami. |
Sponsored by Montgomery County Economic Development Corporation Drive or take the metro in any direction within Montgomery County, Maryland, and you'll come across a life science company responsible for a major innovation. |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now.
|
|
By James Waldron It remains to be seen if Sage Therapeutics’ dalzanemdor can improve function in patients with Huntington's disease, but a phase 2 trial has clarified the science around cognitive decline in patients with the neurodegenerative disorder. |
By James Waldron GLP-1 agonists and their next-gen successors may still be center stage in the red-hot obesity space, but newly launched Syntis Bio is taking a different approach. |
By Helen Floersh Charles River Laboratories has launched a new program to come up with an animal-free alternative to inhalation toxicology tests, marking another move in its larger plan to reduce reliance on animal testing. |
By Zoey Becker After the review board unanimously agreed that Stelara is "unaffordable," the drug could be subject to an upper payment limit in the state. Meanwhile, Stelara biosimilars are only months away from reaching the U.S. market. |
By Conor Hale The University of Oxford spinout's series A round follows up on positive preliminary data from a first-in-human trial earlier this year. |
By Andrea Park In an analysis of thousands of Mallinckrodt’s internal documents, a pair of researchers found evidence of a host of strategies that the pharma allegedly utilized to help sway doctors to prescribe its opioids. |
By Paige Minemyer Thought leaders from across the insurance industry will descend on Las Vegas this week for AHIP's annual conference, kicking off three days of discussions on the biggest issues facing payers. |
Fierce podcastsDon’t miss an episode |
| In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report. |
|
|---|
|
|
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself.
Save $200 when you Register Today!
|
|
| WebinarWatch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
| WhitepaperNew molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
| WhitepaperThis detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
| WhitepaperThis paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
